0001209191-15-083374.txt : 20151203
0001209191-15-083374.hdr.sgml : 20151203
20151203185352
ACCESSION NUMBER: 0001209191-15-083374
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20151201
FILED AS OF DATE: 20151203
DATE AS OF CHANGE: 20151203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kite Pharma, Inc.
CENTRAL INDEX KEY: 0001510580
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
BUSINESS PHONE: (310) 824-9999
MAIL ADDRESS:
STREET 1: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Better Marc
CENTRAL INDEX KEY: 0001609642
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36508
FILM NUMBER: 151268466
MAIL ADDRESS:
STREET 1: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-12-01
0
0001510580
Kite Pharma, Inc.
KITE
0001609642
Better Marc
C/O KITE PHARMA, INC.
2225 COLORADO AVENUE
SANTA MONICA
CA
90404
0
1
0
0
VP, Product Sciences
Common Stock
2015-12-01
4
M
0
9000
0.38
A
10888
D
Common Stock
2015-12-01
4
S
0
905
74.53
D
9983
D
Common Stock
2015-12-01
4
S
0
2772
75.48
D
7211
D
Common Stock
2015-12-01
4
S
0
3664
76.57
D
3547
D
Common Stock
2015-12-01
4
S
0
1215
77.50
D
2332
D
Common Stock
2015-12-01
4
S
0
254
78.53
D
2078
D
Common Stock
2015-12-01
4
S
0
100
80.59
D
1978
D
Common Stock
2015-12-01
4
S
0
90
82.42
D
1888
D
Employee Stock Option (Right to Buy)
0.38
2015-12-01
4
M
0
9000
0.00
D
2023-01-15
Common Stock
9000
78000
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2015.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.09 to $74.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.10 to $76.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.11 to $77.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.11 to $78.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.21 to $79.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
25% of the shares subject to the stock option vested and became exercisable on January 2, 2014, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
/s/ Dave Tanen, Attorney-in-Fact
2015-12-03